NEW YORK (GenomeWeb News) – Myriad Genetics said during its analyst and investor day today that it will launch a new multi-hereditary cancer panel, called myRisk Hereditary Cancer, by the end of this year that will replace its existing BRACAnalysis and other hereditary cancer tests by the summer of 2015.

The new panel will initially focus on breast, colon, ovarian, endometrial, and pancreatic cancer, as well as melanoma, and will expand to lung, prostate, and other cancers in the future, Mark Capone, president of Myriad Genetics Laboratories, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.